Garrison Point Advisors’s Quest Diagnostics DGX Stock Holding History

Garrison Point Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$560K	Hold	2,856	–	–	0.26%	101
2025 Q4	$496K	Hold	2,856	–	–	0.22%	103
2025 Q3	$544K	Hold	2,856	–	–	0.23%	100
2025 Q2	$513K	Hold	2,856	–	–	0.24%	100
2025 Q1	$483K	Hold	2,856	–	–	0.23%	102
2024 Q4	$431K	Buy	+2,856	New	+$444K	0.2%	103

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Garrison Point Advisors's DGX Position: Q1 2026 in Review

Garrison Point Advisors held its Quest Diagnostics (DGX) position steady in Q1 2026 at 2,856 shares worth $560K. The position accounts for 0.26% of the portfolio, ranked #101.

Garrison Point Advisors first reported a position in DGX in Q4 2024 and has held it in 6 quarters since. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Garrison Point Advisors held 2,856 shares of Quest Diagnostics worth $560K as of Q1 2026.
Garrison Point Advisors left its Quest Diagnostics share count unchanged in Q1 2026.
Quest Diagnostics made up 0.26% of Garrison Point Advisors's portfolio in Q1 2026, its #101 holding.
Garrison Point Advisors first reported a position in Quest Diagnostics in Q4 2024 and has held it in 6 quarters since.
1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Garrison Point Advisors's 13F filing for Q1 2026, filed 13 May 2026.